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WHILE THERE IS NO definitive etiology of decompression sickness (DCS), it is believed that bubble formation as a result of rapid decompression initiates a cascade of undefined events leading to the manifestation of DCS (11) . In cardiopulmonary DCS, bubble formation can cause right heart failure (7) or compromise blood flow to critical tissue beds such as the central nervous system (17) . Standard therapy for DCS is recompression followed by controlled, staged decompression in a hyperbaric chamber. However, DCS onset is most often geographically remote from advanced medical assets, particularly assets that include hyperbaric chambers. This is certainly true in disabled submarine rescue and some recreational diving. Methods to mitigate the effects of DCS without hyperbaric chambers may improve clinical outcomes as there is evidence to suggest adverse effects of delaying recompression on severe DCS (1, 8, 15, 25) .
Perfluorocarbons (PFCs) are synthetic fluorinated hydrocarbons that have shown benefit in preventing and treating the manifestations of severe DCS in animal models. Compared with normal saline or plasma, PFCs can carry several times as much respiratory gas (such as oxygen and nitrogen) (34) . Hence, when emulsified for intravenous (IV) delivery, PFCs appear as ideal compounds to treat the bubble formation component of DCS by facilitating nitrogen elimination and enhancing oxygen delivery to tissue that may have decreased blood flow (3, 16, 19, 41) . In swine and rodent models, IV emulsified PFCs have reduced severe DCS incidence when used prior to onset, and reduced mortality when administered after onset (9, 27, 33) .
However, one concern for PFC emulsions is its association with an increase in pulmonary artery pressure (PAP) observed in certain species (16, 32, 35) . This finding has been attributed to pulmonary macrophages and complement activation (14, 37) . Since severe DCS is also associated with elevated PAP, there is a rational concern for any deleterious effects of PFC treatment. In large-animal studies evaluating this disease/treatment combination, mean PAP did not appear elevated above control therapy in swine, yet did appear elevated above control therapy in a sheep DCS model (32, 35) .
The studies cited used unbalanced mixed-sex populations. Sex-related studies of DCS onset and severity have yielded conflicting results and to our knowledge sex differences in PFC therapy have not been examined (2, 39) . This balanced mix-sex swine study aims to primarily evaluate the cardiovascular effects of sex differences and treatment with the PFC emulsion, Oxycyte (Oxygen Biotherapeutics, Inc., Morrisville, NC), at a dose of 5 ml/kg following onset of DCS.
We hypothesized that Oxycyte will improve the hemodynamic profile (especially PAP) when used in the treatment of severe DCS.
METHODS
The study protocol was reviewed and approved by the Walter Reed Army Institute of Research/Naval Medical Research Center Institutional Animal Care and Use Committee in compliance with all applicable Federal regulations governing the protection of animals in research. The institutional animal care facility is fully AAALAC accredited, and the veterinary staff is familiar with our swine model for DCS.
Swine were purchased from a single vendor and acclimatized for a minimum of 5 days prior to experimentation. Swine were housed singly and fed 2-2.5% of body weight twice daily (Lab diet Mini Pig Grower, Quality Lab Products, Elkridge MA); water was provided ad libitum. On the evening prior to the experiment the animal was fasted overnight but allowed free access to water.
Surgical Preparation of Swine
Thirty-two Yorkshire swine (16 male; 16 female; 25.20 Ϯ 2.28 kg) were randomized into four groups: 1) PFC/Males were males treated with PFC; 2) Saline/Males were control males treated with normal saline; 3) PFC/Females were females treated with PFC; and 4) Saline/Females were control females treated with saline. On the day of experiment, swine were transported in a kennel to a surgical preparation room where they were premedicated with ketamine (10 -20 mg/kg; Vedco, Saint Joseph, MO) and xylazine (1-2 mg/kg im; Akom, Decatur, IL) and intubated after further induction with inhaled isoflurane via a snout cone. An ear vein was catheterized (20 -22 gauge ϫ 1 in.) for intravenous access (fluid maintenance and medication administration). In the prone position swine were shaved for electrode and sensor placement.
Subsequently, each animal was taken into the surgical room and placed in the supine position. Anesthesia was maintained with inhaled isoflurane (2%) in room air via a GE S5 ADU Carestation (GE Healthcare, Madison, WI). The right superficial femoral artery was exposed and a 12-in. PE-90 catheter (ReCathCo Allison Park, PA) was introduced into the artery and advanced centrally into the femoral artery for blood sampling. In similar fashion the left superficial femoral arterial branch was accessed and a pressure transducer (for continuous blood pressure monitoring) was inserted (Mikro-Tip Pressure Catheters; Millar Instruments, Houston, TX). Simultaneous to arterial catheterization, a pulmonary artery catheter was introduced via surgical exposure of the right external jugular vein (CCOmbo V 7.5 F; Edwards Lifesciences, Irvine, CA). If the right jugular vein was unusable for any reason during catheterization, the process was repeated on the left side. After completing the surgical procedures the animal was placed in a Panepinto sling, Buprenorphine (Buprenex, 0.1 mg/kg im) was administered, isoflurane anesthesia was discontinued, and the animal was extubated. The animal was then transported in the Panepinto sling to the hyperbaric chamber. Any subsequent distress was treated with diazepam (0.1 mg/kg iv every 5 min).
Monitoring Devices and Data Acquisition
The pulmonary artery catheter was connected to a cardiac output monitor (Vigilance, Edwards Life Sciences, Irvine, CA) and pulmonary arterial and central venous lines were connected to pressure transducers (Argon Medical Devices, Athens, TX). However, continuous CO via the pulmonary artery catheter was unreliable (attributed to the small size of the swine and the fixed position of the thermal element). Hence CO was monitored by noninvasive cardiac output (NICOM) and HR was measured by bioreactance (NICOM, Cheetah Medical, Vancouver, WA). The Mikro-Tip catheter pressure transducer was connected to a blood pressure monitor (Blood pressure analyzer, Micro-Med, Louisville, KY). Electrocardiogram (ECG) electrodes (disposable infant/neonatal electrode; Grass/AstroMed, Warwick, RI) were placed on the shoulders with waveforms generated by a Cerberus amplifier (Quintlab, Hungary). A pulse oximeter (Vet/Ox 4404, Heska, Waukesha, WI) sensor was placed on the tail for use before and after hyperbaric exposure. Additionally, the infusion line was monitored with an ultrasonic flowmeter (T201 Transonic Systems, Ithaca, NY). Pressure of the diving chamber was measured with a digital pressure gauge (CPG 2500, Mensor, SanMarcos, TX); O2 and CO2 concentrations were measured by a gas analyzer (O2/CO2 monitor 9500, Alpha Omega Instrument, Lincoln, RI). Analog waveforms were digitized and recorded on a Dash 32HF (Astro-Med, West Warwick, RI). Serial data were displayed and recorded directly into a laptop (Precision M6400, Dell, Round Rock, TX) and a NI USB-232 card (National Instruments, Austin, TX). To calibrate pressure transducers a water column was used with 0 and 136 cm heights (0 and 100 mmHg). For calibrating ECG, 0.5-and 1-mV ECG signals were generated with a patient simulator (Patient Simulator 214A, Dynatech Nevada, Carson City, NV) before and after the measurement.
Hyperbaric Chamber
The hyperbaric chamber was a 707.92-liter cylinder (Bethlehem Steel, Bethlehem, PA), equipped with hull penetrations for physiological and environmental sensor cables and for gas inflow/outflow, and a platform for insertion of a cart/sling for holding the swine. CO 2 accumulated during hyperbaric exposure was removed with a scrubber (CO 2 Scrubber 3.80.1080, IHC Hytech). Swine were continuously monitored by two video cameras situated on viewports outside of the chamber during hyperbaric exposure.
Experimental Protocol
An experimental flow diagram is shown in Fig. 1 . Baseline data were recorded for 30 min after which the intravascular pressure monitors were disconnected and the swine was inserted into the hyperbaric chamber. Sensors for ECG and NICOM were reconnected to through-hull cables to enable continuous monitoring during hyperbaric exposure. The chamber was then compressed to 200 feet of sea water (fsw) using a nonlinear compression profile described in detail elsewhere (27) . The total time of compression and maintenance at 200 fsw was 31 min; the chamber was then decompressed to atmospheric pressure at 30 fsw/min. Throughout the hyperbaric exposure, animals breathed chamber atmosphere air maintained at 21% (Ϯ0.02%) O 2 and a surface equivalent of CO2 Ͻ 0.5% (Ϯ0.05%).
After reaching surface pressure the swine was removed from the chamber and reconnected to the pressure transduction cables. The animal was closely observed for any signs of cutis marmorata (CM), a morbiliform purple discoloration of the skin that is a form of DCS (skin bends) and is a predictor for DCS severity in swine (4). Time 0 was defined as CM onset at which time either PFC or normal saline was infused at 5 ml/kg over 10 min as well as 100% O 2 supplied for 60 min using a cone mask (Smith Medical North America, Waukesha, WI). Animals were observed and data collected for 90 min after CM onset.
Arterial blood gas samples were collected during the baseline period and at 30, 60, and 90 min following the CM onset and analyzed by an ABL 835 blood gas analyzer (Radiometer Copenhagen, Denmark). On completion of the 90-min observation period, ketamine (20 mg/kg iv) was administered, and all sensors, electrodes, and arterial catheters were removed. The jugular introducer sheath was guide-wire exchanged for a single-lumen central catheter and sutured into place. All wounds were closed. A second dose of buprenorphine (0.01-0.1 mg/kg) was administered and the animal was allowed to recover.
After recovery, swine were returned to their holding pens and observed for any discomfort or paralysis. Any evidence of discomfort was treated with buprenorphine (0.1 mg/kg im), 2-3 times daily as needed. Paralyzed animals were observed at least four times per 24-h period for interventions that included hand feeding, watering, manual bladder expression, and repositioning. If their oral intake appeared inadequate animals were periodically placed in a Panepinto sling for intravenous fluids. All animals that survived the initial experimental phase were maintained for 48 h post-hyperbaric exposure.
After completion of the observation period (48 h), animals received heparin (100 IU/kg; Sagent Pharmaceuticals, Schaumberg, IL) and were transported to the necropsy suite for humane euthanization with intravenous Euthasol (1-1.5 ml/10 lbs; Virbac Animal Health, Fort Worth, TX). Whole body perfusion fixation was performed (10% buffered formalin) and the brain and spinal cord were harvested as well as samples of spleen, kidney, liver, heart, lung, small and large intestines, and blood. Animals that did not survive to the study end point (48 h) did not undergo pathological evaluation. Pathology results are reported separately.
gram or via MATLAB (The Mathworks, Natick, MA); statistical analyses were performed using either Excel or MATLAB. Group values for animal weight, time of DCS onset, time of maximum PAP elevation, and means of cardiovascular parameters were statistically compared using a t-test. In addition to the above groups, PFC irrespective of sex was compared with saline control, and males irrespective of treatment were compared with females.
Data points were extracted from analog data at 30-s intervals and a moving 10-min interval mean (20 data points) was calculated in MATLAB for each group. Setting time of DCS onset as time ϭ 0, 90 min of moving means were grouped into nine 10-min intervals for ANOVA analysis using Excel.
Mean values of blood gas data (pH, PCO 2, PO2, and lactate concentration), collected at baseline and at 30, 60, and 90 min after DCS onset were compared using a t-test for two-group comparisons, and ANOVA for four-group comparisons.
RESULTS

General
There were no significant weight differences between groups. However, there was significant variability in baseline cardiovascular parameters among the four treatment/sex groups (Table 1) .
DCS Onset
All animals developed CM and were diagnosed with DCS. Prior to any treatment initiation, time to CM (DCS onset) was not significantly different when comparing all animals randomized to PFC to all animals randomize to saline (10.48 vs. 8.28 min post-surfacing, P ϭ 0.24). DCS onset was quicker in females than males (7.30 vs. 11.46 min post-surfacing, P ϭ 0.02). Mean CO, PAP, SAP, and HR were elevated in all groups during the period between reaching surface pressure and DCS onset. These post-surfacing preonset elevations were all statistically significant (P Ͻ 0.05) compared with group mean baselines except for CO in males randomized to PFC treatment and HR in females randomized to PFC treatment ( Table 2 , Fig. 2) .
Hemodynamics Throughout the 90-min Observation Period
When the 90-min post-DCS observation period was taken as a whole, CO and PAP were significantly elevated in the PFC treatment group (male and female combined); SAP was not significantly different, and HR was significantly elevated in the saline group (male and female combined). Females (treatment and control combined) exhibited higher CO, no difference in PAP or SAP, and a lower HR compared with the males (treatment and control combined). This latter difference was most pronounced when considering a markedly elevated HR in the saline control males ( Table 2 , Fig. 2 ). Mean time to peak PAP was not significantly different between the PFC-and saline-treated groups (8.75 and 7.07 min post-CM onset, respectively). In both PFC-and saline-treated females, peak PAP was reached sooner than in their male counterparts (6.41 and 9.69 min post-CM onset, respectively; P ϭ 0.0069). However, the peak PAP values were not significantly different (Table 3) .
Morbidity and mortality
Although this study was not powered to detect survival differences, survival to 90 min and to 48 h were not statistically different between swine treated with PFC compared with saline-treated controls (75% vs. 88%, P ϭ 0.16; and 63% vs. 81%, P ϭ0.08, respectively). Similarly, there was no statistically significant difference in incidence of paralysis between PFC-and saline-treated swine (25% vs. 19%, P ϭ 0.33) and no statistically significant differences in survival at the 90-min postexposure or 48-h end points across the four groups: saline male (88%, 75%), saline female (88%, 75%), PFC male (75%, 63%), and PFC female (75%, 63%). Finally, there was no statistically significant difference in incidence of paralysis among the four groups: saline male (13%), saline female (25%), PFC male (25%), and PFC female (25%).
Normalized Data
Sex difference hemodynamics due to DCS. The baseline differences in CO and PAP led us to compare changes in group means normalized to baseline. Comparing percentage changes of group mean values for males vs. females treated only with saline, DCS onset coincides with a significant difference in HR, with female values remaining at or near baseline and male values being elevated. Cardiac outputs were initially elevated in both males and females postsurfacing, but then dropped to near baseline in males and below baseline in females. Mean PAP increased in both males and females, but more so in females. Mean SAP also increased in both males and females, but in this case more so in males (Table 4 , time period 0 -10, and Fig. 2) .
Male vs. female: within-treatment sex comparisons. Among the saline-treated controls, females exhibited lower CO throughout, and elevated PAP during the initial 70 min of observation compared with saline-treated males. Control males and females both demonstrated an increased SAP; however, the increase in females was less robust than their male counterparts (Fig. 2, Table 4 ).
Among PFC-treated swine, CO, PAP, and SAP were significantly increased in females compared with males during the initial 10-min observation interval. CO in the females decreased below male values after 30 min. PAP in females was lower than in males in the 20-to 40-min interval, although it was elevated above baseline in both groups for the entire 90-min observation period. SAP remained elevated in all time periods in PFC-treated females compared to PFC treated males (Fig. 2, Table 5 ).
PFC vs. saline treatment comparisons. Among females, PFC-treatment significantly increased CO in the initial period after DCS onset, followed after 30 min by a lower CO than observed in the saline group. PAP in PFC-treated females was below that seen in the saline group in the initial period, but remained persistently elevated after 40 min. SAP remained elevated above baseline in the PFC-treated female group during the full post-hyperbaric exposure period (Fig. 2, Table 6 ).
Among males, treatment with PFC produced a lower CO and HR and higher PAP throughout the 90-min observation period compared with male/saline controls. Male/saline controls had a significantly elevated PAP following onset of DCS but returned to baseline by 70 min. However, unlike PFC-treated females, the SAP for both PFC-treated and saline-treated males showed only a transient initial elevation that was not present during the majority of the 90-min observation period (Fig. 2, Table 7 ).
Arterial blood gas and lactic acid level measurements at baseline and during the 90-min observation period showed no significant differences except for pH at 90 min.
DISCUSSION
In this study we aimed to evaluate any significant differences in cardiovascular parameters with severe DCS between sexes in a swine model treated with emulsified PFC. Significant differences were noted between sexes regarding the rapidity of DCS onset as well as several cardiovascular parameters with and without PFC treatment. Although sex differences in DCS have been hypothesized for several years, no conclusive evidence has been demonstrated. Hypothetically, human females may be at greater risk of DCS due to relatively higher body fat relative to males. Differences in nitrogen absorption have been hypothesized and differences in nitrogen elimination between sexes have been demonstrated (6, 22, 30) . Hart and Strauss (18) also demonstrated via in vivo gas measurements on human volunteers that females release subcutaneous N 2 more slowly than males, although values for muscle were similar. They theorized that this difference in N 2 release was due to differences in tissue perfusion, although no correction for body fat content was mentioned. With a prospective study of altitude DCS, Webb et al. (40) demonstrated that it was body mass index and maximal oxygen consumption (but not sex) that correlated with actual DCS risk. Interestingly, they showed that females on hormonal contraceptives were at higher risk for DCS in the last 2 wk of their menstrual cycle than those not on such therapy. In our study no attempt was made to determine the hormonal milieu of the swine.
Although mixed-sex animal studies have been performed, a literature search found none that were designed explicitly to evaluate sex differences in animal models of DCS. In this report females had a quicker DCS onset compared with males. The significantly earlier DCS onset seen in females was not associated with any obvious differences in hemodynamics immediately preceding DCS; all groups showed an increase in CO, SAP, and PAP in the period immediately preceding the onset of DCS. However, after the onset of DCS all females demonstrated an earlier time to peak PAP compared with males. The effect of PFC between sexes was less clear-cut. All PFC-treated animals exhibited an increase in PAP throughout the full 90-min observation period. With respect to sex, PFCtreated females compared with female controls exhibited a relatively higher CO and lower PAP in the initial post-DCS period, but ϳ30 min into the 90-min observation period this reversed to relatively decreased CO and persistently elevated PAP. Among controls data suggest that female swine had more cardiovascular compromise with DCS (controls with higher PAP and SAP and lower CO than males). PFC-treated females had a more favorable initial cardiovascular response but more deranged cardiovascular findings later, with persistently elevated PAP and decreased CO.
PFC-treated males compared with male controls were likewise interesting. Taken as a whole, PAP was elevated in PFC treated males and CO was decreased during the full 90-min observation period. Initially, SAP increased in the both control and PFC males but then decreased in the PFC-treated group after the initial 10-min interval, returning near baseline. Although such a pattern of increased PAP and decreased CO and SAP raises concern about right heart failure (20) , mortality between the male PFC and control groups in this study was not significantly different.
Elevated PAP with DCS has been described in other PFC studies using swine and sheep (32, 35) . In animal models, an elevated PAP with severe DCS and venous gas embolism has been correlated with increased bubble counts (5, 7, 38) . This is consistent with capillary obstruction by bubbles as the mechanism, but is also consistent with increased vasoreactivity secondary to bubble endothelial interaction as the cause (23) .
With evidence that all PFC-treated animals had a higher PAP during the 90-min observation period, concern for the effect(s) of emulsified PFC is heightened. Contrary to our results, Spiess et al. (35) showed no difference in PAP with PFC treatment of severe DCS. However, that study differed from ours in that PFC was infused before DCS onset and PAP rise was reported at discreet 15-min time points. In line with the swine data reported here, it appears that sheep with severe DCS also demonstrate evidence of further elevation in PAP with PFC therapy (32) .
An elevated PAP in Artiadactyla (swine, sheep, goats, etc.) without DCS has been described with PFC emulsions and has been attributed to a similarly transient PAP rise with other small particulate injections (14) . Small particle liposomes were demonstrated to cause a transient increase in PAP that correlated with liposome retention in the lung and pulmonary macrophages (29) . This rise was correlated with marked rise in systemic levels of TXB2 (metabolite of thromboxane). Inhibitors of the arachidonic acid pathway appear to block this response. Although intrapulmonary macrophages were hypothesized as the source of the TXB2, the authors (admittedly) did not confirm this. Szebeni et al. (36) subsequently demonstrated that complement activation appeared to play a significant role in this reaction; liposome size and composition had a strong influence on the degree of PAP with large (Ͼ0.35 m) multilamellar compounds causing a robust rise in PAP, and small (Ͻ0.19 m) unilamellar compounds having little or no effect on PAP. This so-called complement activation pseudoallergy (CARPA) with liposomes was reproduced in a swine model using human C3a and C5a administration. Of note, CARPA has been described in several species to include the Artiadactyla, canines, rats, as well as humans.
Most emulsified PFC compounds are lipid particles, with a median particle size of 0.2-0.25 m (however with some particles up to 0.6 m) and hence within a particle size range where elevated PAP would potentially be anticipated (34, 36) . Although there is no evidence of elevated PAP in humans who have received Oxycyte, elevated PAP was reported in a patient receiving an infusion of an older-generation PFC (Fluosol) (37) . Further complicating matters, the dynamics of PFC lipid particles in the face of intravascular bubbles is essentially unknown and conceivably may alter the "biologic" particle size or activity.
Despite evidence of adverse hemodynamic effects of PFC emulsion in swine (and sheep), PFCs have a long history in the prevention of DCS as well as improving mortality after DCS onset in animal models (9, 27) . This improvement could be due to overall higher oxygen content, enhanced nitrogen elimina- tion, or surfactant properties that may limit arterial bubble derangements (12, 13, 26, 31, 32) . Why female swine manifested earlier onset and less time to peak PAP can only be hypothesized. Possible explanations include differences in body composition, hormonal milieu, or vascular anatomic differences. Additionally, we did not evaluate any differences in skin composition to include adipose vascular supply as the cause for the earlier onset of CM.
Likewise, the basis for groups demonstrating differences in PAP and CO at baseline is unknown. Certainly some of the differences, such as a PAP difference of 4 mmHg among groups, would not be surprising and reflects the small standard deviations from analysis of intervals. As PAP was our primary interest we are satisfied with these statistically, but relatively minor, differences at baseline. However, the larger differences seen at baseline CO may be clinically relevant. We cannot exclude differences in anesthetic and sedative effects between sexes. Although not presented here, we observed no differences in body temperature or level of hemoglobin, both factors that can affect CO.
Our study is not without flaw, the most significant being the entirely noninvasive measurement of CO. Unfortunately, the pulmonary artery catheter for continuous CO was unreliable in this small swine model. Although originally designed to serve as our gold standard, the small swine size did not allow for proper positioning of the thermal element. The bioreactancebased noninvasive CO measurement we used is based on an analysis of relative phase shifts of an oscillating current that occur when this current traverses the thoracic cavity, as opposed to traditional bioimpedance-based systems, which rely only on measured changes in signal amplitude. Noninvasive CO monitoring using similar bioimpedance has shown reliable measurements when compared with oxygen consumption (Fick) techniques and demonstrated a high correlation in a swine model using cardiopulmonary bypass to regulate CO (21, 24) . Comparing "gold-standard" CO measurements with the bioreactance measurement of NICOM has been useful in predicting fluid responsiveness in patients with shock and shorter hospital stays in trauma patients (10, 28) . Admittedly, we find no studies involving NICOM CO measurements in DCS and, as is the case with other invasive and noninvasive techniques, its use has not been validated in DCS.
Conclusions
Female swine appear to have earlier DCS onset and more severe hemodynamic manifestations (as judged by PAP) compared with male swine. Oxycyte was associated with a higher PAP in both sexes with severe DCS. Further study into the mechanisms of these findings should be examined before considering human studies with Oxycyte in DCS.
